Top-Rated StocksTop-RatedNASDAQ:CRNX Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Free CRNX Stock Alerts $37.93 -1.00 (-2.57%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$37.52▼$39.0650-Day Range$35.50▼$46.0352-Week Range$15.23▼$47.58Volume773,547 shsAverage Volume691,589 shsMarket Capitalization$2.64 billionP/E RatioN/ADividend YieldN/APrice Target$50.82 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Crinetics Pharmaceuticals alerts: Email Address Crinetics Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside37.3% Upside$52.09 Price TargetShort InterestBearish6.81% of Shares Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment0.53Based on 6 Articles This WeekInsider TradingSelling Shares$1.52 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.20) to ($3.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.26 out of 5 starsMedical Sector164th out of 947 stocksPharmaceutical Preparations Industry71st out of 432 stocks 4.5 Analyst's Opinion Consensus RatingCrinetics Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.09, Crinetics Pharmaceuticals has a forecasted upside of 37.3% from its current price of $37.93.Amount of Analyst CoverageCrinetics Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.81% of the outstanding shares of Crinetics Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCrinetics Pharmaceuticals has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Crinetics Pharmaceuticals has recently increased by 5.10%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCrinetics Pharmaceuticals does not currently pay a dividend.Dividend GrowthCrinetics Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCrinetics Pharmaceuticals has received a 46.37% net impact score from Upright. Crinetics Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Crinetics Pharmaceuticals is -0.62. Previous Next 3.1 News and Social Media Coverage News SentimentCrinetics Pharmaceuticals has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Crinetics Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest6 people have searched for CRNX on MarketBeat in the last 30 days. MarketBeat Follows8 people have added Crinetics Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Crinetics Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,521,509.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of Crinetics Pharmaceuticals is held by insiders.Percentage Held by Institutions98.51% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Crinetics Pharmaceuticals are expected to decrease in the coming year, from ($3.20) to ($3.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crinetics Pharmaceuticals is -10.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Crinetics Pharmaceuticals is -10.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCrinetics Pharmaceuticals has a P/B Ratio of 4.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About Crinetics Pharmaceuticals Stock (NASDAQ:CRNX)Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). It is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. The company was incorporated in 2008 and is headquartered in San Diego, California.Read More CRNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRNX Stock News HeadlinesMarch 19, 2024 | globenewswire.comCrinetics' Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly PatientsMarch 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Crinetics Pharmaceuticals as Paltusotine Shows Promising Phase 2 Results and Market PotentialMarch 19, 2024 | Porter & Company (Ad)My next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.March 12, 2024 | seekingalpha.comCrinetics reports encouraging Phase 2 data for carcinoid syndrome drugMarch 12, 2024 | globenewswire.comCrinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid SyndromeMarch 12, 2024 | finanznachrichten.deCrinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 11, 2024 | markets.businessinsider.comCrinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 11, 2024 | globenewswire.comCrinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 19, 2024 | Porter & Company (Ad)My next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.March 10, 2024 | americanbankingnews.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Up to $42.50March 9, 2024 | americanbankingnews.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of "Moderate Buy" from AnalystsMarch 6, 2024 | msn.comCiti starts Crinetics at buy, cites upcoming data for lead drugMarch 1, 2024 | investing.comCrinetics Pharmaceuticals secures $350 million in placementMarch 1, 2024 | finance.yahoo.comCrinetics Pharmaceuticals Full Year 2023 Earnings: Misses ExpectationsMarch 1, 2024 | finance.yahoo.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | seekingalpha.comCrinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)February 29, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Crinetics Pharmaceuticals (CRNX) and Inhibrx (INBX)February 29, 2024 | markets.businessinsider.comThe Analyst Verdict: Crinetics Pharmaceuticals In The Eyes Of 6 ExpertsFebruary 28, 2024 | finance.yahoo.comCrinetics Pharmaceuticals Inc (CRNX) Reports Increased R&D Investment Amidst Net Loss ...February 28, 2024 | globenewswire.comCrinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 28, 2024 | marketwatch.comCrinetics Pharma Shares Hit 52-Week High After Oversubscribed Private PlacementFebruary 28, 2024 | globenewswire.comCrinetics Pharmaceuticals Announces Oversubscribed $350 Million Private PlacementFebruary 27, 2024 | benzinga.comCrinetics Pharmaceuticals Earnings PreviewFebruary 23, 2024 | benzinga.comCrinetics Pharmaceuticals Stock (NASDAQ:CRNX), Short Interest ReportFebruary 17, 2024 | finance.yahoo.comCRNX Mar 2024 35.000 putFebruary 16, 2024 | finance.yahoo.comCRNX Sep 2024 55.000 callFebruary 15, 2024 | msn.comIronwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q4See More Headlines Receive CRNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/19/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CRNX CUSIPN/A CIK1658247 Webwww.crinetics.com Phone(858) 450-6464FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Target$52.09 High Stock Price Target$68.00 Low Stock Price Target$35.00 Potential Upside/Downside+34.0%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-214,530,000.00 Net Margins-4,223.27% Pretax Margin-5,216.32% Return on Equity-52.93% Return on Assets-45.54% Debt Debt-to-Equity RatioN/A Current Ratio13.07 Quick Ratio13.07 Sales & Book Value Annual Sales$4.01 million Price / Sales658.34 Cash FlowN/A Price / Cash FlowN/A Book Value$8.07 per share Price / Book4.70Miscellaneous Outstanding Shares69,600,000Free Float64,724,000Market Cap$2.64 billion OptionableOptionable Beta0.62 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. R. Scott Struthers Ph.D. (Age 62)Founder, President, CEO & Director Comp: $870.69kDr. Stephen F. Betz Ph.D. (Age 58)Founder & Chief Scientific Officer Comp: $618.58kMr. Marc J. C. Wilson (Age 45)Chief Financial Officer Comp: $585.54kMr. James Hassard (Age 58)Chief Commercial Officer Comp: $513.34kDr. Dana Pizzuti M.D. (Age 68)Chief Development Officer Comp: $493.62kMr. Jeff E. Knight (Age 53)Chief Operating Officer Comp: $237.64kMs. Garlan AdamsGeneral Counsel & Corporate SecretaryMs. Adriana Cabre M.B.A.Chief Human Resources OfficerDr. Alan S. Krasner M.D. (Age 61)Chief Medical Officer Comp: $571.97kMr. Kevin CappsHead of Intellectual PropertyMore ExecutivesKey CompetitorsHUTCHMEDNASDAQ:HCMGemini TherapeuticsNASDAQ:GMTXIndiviorNASDAQ:INDVMorphoSysNASDAQ:MORMoonLake ImmunotherapeuticsNASDAQ:MLTXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 95,417 shares on 3/11/2024Ownership: 5.032%Wellington Management Group LLPSold 395,130 shares on 3/5/2024Ownership: 4.663%Fisher Asset Management LLCBought 387,435 shares on 3/5/2024Ownership: 0.634%Goldman Sachs Group Inc.Bought 97,575 shares on 3/1/2024Ownership: 0.973%Teachers Retirement System of The State of KentuckyBought 5,386 shares on 2/26/2024Ownership: 0.061%View All Insider TransactionsView All Institutional Transactions CRNX Stock Analysis - Frequently Asked Questions Should I buy or sell Crinetics Pharmaceuticals stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CRNX shares. View CRNX analyst ratings or view top-rated stocks. What is Crinetics Pharmaceuticals' stock price target for 2024? 12 analysts have issued twelve-month price targets for Crinetics Pharmaceuticals' shares. Their CRNX share price targets range from $35.00 to $68.00. On average, they anticipate the company's share price to reach $52.09 in the next twelve months. This suggests a possible upside of 37.3% from the stock's current price. View analysts price targets for CRNX or view top-rated stocks among Wall Street analysts. How have CRNX shares performed in 2024? Crinetics Pharmaceuticals' stock was trading at $35.58 at the beginning of 2024. Since then, CRNX shares have increased by 6.6% and is now trading at $37.93. View the best growth stocks for 2024 here. Are investors shorting Crinetics Pharmaceuticals? Crinetics Pharmaceuticals saw a increase in short interest in the month of February. As of February 29th, there was short interest totaling 4,740,000 shares, an increase of 5.1% from the February 14th total of 4,510,000 shares. Based on an average trading volume of 791,300 shares, the days-to-cover ratio is presently 6.0 days. View Crinetics Pharmaceuticals' Short Interest. When is Crinetics Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CRNX earnings forecast. How were Crinetics Pharmaceuticals' earnings last quarter? Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) issued its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.89) by $0.01. Crinetics Pharmaceuticals had a negative net margin of 4,223.27% and a negative trailing twelve-month return on equity of 52.93%. Crinetics Pharmaceuticals's quarterly revenue was down 100.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.84) earnings per share. What ETF holds Crinetics Pharmaceuticals' stock? iShares Micro-Cap ETF holds 121,735 shares of CRNX stock, representing 0.25% of its portfolio. What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO? 6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend. What other stocks do shareholders of Crinetics Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC). When did Crinetics Pharmaceuticals IPO? (CRNX) raised $80 million in an initial public offering on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO. Who are Crinetics Pharmaceuticals' major shareholders? Crinetics Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.24%), Vanguard Group Inc. (5.03%), Point72 Asset Management L.P. (5.12%), Wellington Management Group LLP (4.66%), Price T Rowe Associates Inc. MD (4.50%) and Price T Rowe Associates Inc. MD (4.50%). Insiders that own company stock include Ajay Madan, Alan Seth Krasner, Coelho Rogerio Vivaldi, Dana Pizzuti, Jeff E Knight, Marc Wilson, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers and Stephen F Betz. View institutional ownership trends. How do I buy shares of Crinetics Pharmaceuticals? Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CRNX) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.